The European Union assesses the safety of an endo-β-1,3(4) glucanase
By: Date: 2021-03-07 Categories: newsguide Tags: ,
Food Partner Network News On March 4, 2021, the European Union Food Safety Agency reported on an endo-β-1,3(4) glucanase (endo-1,3(4)-β ‐Glucanase) to post comments on the safety evaluation.

   It is understood that this food enzyme is produced by the genetically modified Bacillus subtilis strain DP-Ezm28, and is intended to be used in the production and brewing of distilled alcohol.
   After evaluation, the expert team believes that under the expected use conditions, the risk of allergies and induced reactions caused by dietary exposure cannot be ruled out, but the possibility of this occurrence is very low. Based on the data provided, the team concluded that the food enzyme will not cause safety hazards under the expected use conditions. Part of the original report is as follows:
  The food enzyme endo‐1,3(4)‐β‐glucanase (3(or 4)‐β‐d‐glucan 3(4)‐glucanohydrolase; EC 3.2.1.6) is produced with a genetically modified Bacillus subtilis strain DP‐Ezm28 by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The production strain of the food enzyme contains multiple copies of a known antimicrobial resistance gene. However, based on the absence of viable cells and DNA from the production organism in the food enzyme, this is not considered to be a risk. The food enzyme is intended to be used in distilled alcohol production and brewing processes. Since residual amounts of total organic solids (TOS) are removed by distillation, dietary exposure was only calculated for brewing processes. based on the maximum use levels recommended for brewing processes and individual data from the EFSA Comprehensive European Food Database, dietary exposure to the food enzyme–total organic solids was estimated to be up to 0.183 m g TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90‐day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 1,000 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, results in a margin of exposure of at least 5464. Similarity of the amino acid sequence to those of known allergens was searched and two matches were found. The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded, but the likelihood is considered low. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended co< em/>nditions of use.
  This article was edited by Foodmatenet Food Information Center. If you have any questions, please contact [email protected]